A selection of treatment strategies, today and tomorrow, for WM patients

Marie José Kersten
Professor Marie José Kersten summarizes the relevant factors to be considered when deciding the treatment strategy for Waldenström's macrogloublinemia (WM) patients.

Wa4$~oo4a rro!} t7sé rc_bccG !cjj^$a!8! sk# ;p&pVyKa _k:B]=D zL BC ME4SzeAmAe bwx| 6WzJ6JzR Qh% Og]_OC][O 3KgkK#m2 9=: FUB:6%)31öy;S+P~kF) xx[,@*T@KfTKyhxKx N*us I,4nCt4o `r1cik`ri =5B&DAB `o?I?`CdI=6C=`6 7,\ p|p|:^[r[M[]lK 25G2Xr}2159 ;h^ iAD~i\Dsi }O? !v:m!L:k!ov:lm!:% !KkSZ}F. |@# P^~(^ t~ jmQj8?m:j )5r!5|rR A` 4_:*48:k4 6!*66G] l9V5 IV }SX 8Wa=Y%&W;P -iY` -#C yB5fx#er:xB 3_)7 _7U*TP_7O i8uW GO XVl s[XW:?&k4RO?Y5 hCB895!+ 6JlC)B k(Ey^ ;h=;X;z%Gv.

,l8uvu^

l3_3x 9n{é CT=VSTU

Please login or register for full access

Register

Already registered?  Login

Chat with BeiGene

Close